CY1124689T1 - Trans-αντιγραφοymeno rna - Google Patents

Trans-αντιγραφοymeno rna

Info

Publication number
CY1124689T1
CY1124689T1 CY20211100949T CY211100949T CY1124689T1 CY 1124689 T1 CY1124689 T1 CY 1124689T1 CY 20211100949 T CY20211100949 T CY 20211100949T CY 211100949 T CY211100949 T CY 211100949T CY 1124689 T1 CY1124689 T1 CY 1124689T1
Authority
CY
Cyprus
Prior art keywords
rna
present
protein
alphavirus
expression
Prior art date
Application number
CY20211100949T
Other languages
English (en)
Inventor
Tim Beissert
Ugur Sahin
Mario Perkovic
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CY1124689T1 publication Critical patent/CY1124689T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση γενικά σχετίζεται με συστήματα και μεθόδους που είναι κατάλληλες για την παραγωγή πρωτεϊνών υψηλού επιπέδου. Ενώ ένα ή περισσότερα στοιχεία της παρούσας εφεύρεσης προέρχονται από έναν αλφαϊό, η παρούσα εφεύρεση δεν απαιτεί διάδοση σωματιδίων ιού. Συγκεκριμένα, προβλέπεται ένα σύστημα που περιλαμβάνει δύο ξεχωριστά μόρια RNA, καθένα από τα οποία περιλαμβάνει μια αλληλουχία νουκλεοτιδίων που προέρχεται από έναν αλφαϊό: ένα μόριο RNA περιλαμβάνει ένα κατασκεύασμα RNA για την έκφραση της ρεπλικάσης αλφαϊού και ένα μόριο RNA περιλαμβάνει ένα ρεπλικόνιο RNA που μπορεί να αντιγραφεί από την ρεπλικάση σε trans. To κατασκεύασμα RNA για την έκφραση ρεπλικάσης αλφαϊού περιλαμβάνει ένα 5'-κάλυμμα. Το ότι το κάλυμμα 5' είναι κατάλληλο για την αποτελεσματική οδήγηση της έκφρασης ενός διαγονιδίου από το ρεπλικόνιο σε trans αποτέλεσε μια αναπάντεχη ανακάλυψη. Το σύστημα της παρούσας εφεύρεσης επιτρέπει την έκφραση μιας πρωτεΐνης ενδιαφέροντος σε ένα κύτταρο ή οργανισμό, αλλά δεν σχετίζεται με τον ανεπιθύμητο σχηματισμό ιού-σωματιδίου. Επομένως, η παρούσα εφεύρεση είναι κατάλληλη για την αποτελεσματική και ασφαλή παραγωγή μιας πρωτεΐνης ενδιαφέροντος, για παράδειγμα, μια θεραπευτική πρωτεΐνη ή μια αντιγονική πρωτεΐνη, όπως ένα εμβόλιο, σε έναν οργανισμό στόχο. Αντίστοιχες μέθοδοι παραγωγής πρωτεΐνης in vitro και in vivo καθώς και ιατρικές χρήσεις παρέχονται στο παρόν. Η παρούσα εφεύρεση παρέχει επίσης DNA που κωδικοποιεί τα μόρια RNA της εφεύρεσης και κύτταρα που περιλαμβάνουν τα μόρια RNA της εφεύρεσης.
CY20211100949T 2016-03-21 2021-11-03 Trans-αντιγραφοymeno rna CY1124689T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/056160 WO2017162265A1 (en) 2016-03-21 2016-03-21 Trans-replicating rna
PCT/EP2017/055813 WO2017162461A1 (en) 2016-03-21 2017-03-13 Trans-replicating rna

Publications (1)

Publication Number Publication Date
CY1124689T1 true CY1124689T1 (el) 2022-07-22

Family

ID=55586324

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100949T CY1124689T1 (el) 2016-03-21 2021-11-03 Trans-αντιγραφοymeno rna

Country Status (26)

Country Link
US (1) US20200299724A1 (el)
EP (2) EP3433368B1 (el)
JP (2) JP7105193B2 (el)
KR (1) KR102441725B1 (el)
CN (2) CN109328233B (el)
AU (1) AU2017236240B2 (el)
BR (1) BR112018068391A2 (el)
CA (1) CA3017285A1 (el)
CY (1) CY1124689T1 (el)
DK (1) DK3433368T3 (el)
ES (1) ES2896927T3 (el)
HR (1) HRP20211715T1 (el)
HU (1) HUE058889T2 (el)
IL (1) IL261327B1 (el)
LT (1) LT3433368T (el)
MA (1) MA44479B1 (el)
MD (1) MD3433368T2 (el)
MX (1) MX2018011384A (el)
PL (1) PL3433368T3 (el)
PT (1) PT3433368T (el)
RS (1) RS62543B1 (el)
RU (1) RU2752580C2 (el)
SG (1) SG11201807378SA (el)
SI (1) SI3433368T1 (el)
WO (2) WO2017162265A1 (el)
ZA (2) ZA201805520B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2019053056A1 (en) * 2017-09-13 2019-03-21 Biontech Cell & Gene Therapies Gmbh RNA REPLICON FOR EXPRESSING A T CELL RECEPTOR OR ARTIFICIAL LYMPHOCYTIC T CELL RECEPTOR
EP3681993A1 (en) * 2017-09-13 2020-07-22 BioNTech RNA Pharmaceuticals GmbH Rna replicon for reprogramming somatic cells
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US10736957B2 (en) * 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
KR102462990B1 (ko) * 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
EP4171629A1 (en) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
GB202020063D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020061D0 (en) 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
GB202020064D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
CN112852841A (zh) 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
WO2022200574A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022228827A1 (en) 2021-04-26 2022-11-03 Institut Pasteur Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
WO2022234268A1 (en) * 2021-05-04 2022-11-10 Mogrify Limited Cell conversion
WO2022248353A1 (en) 2021-05-24 2022-12-01 Glaxosmithkline Biologicals Sa Adjuvants
US20220396798A1 (en) * 2021-06-12 2022-12-15 Shi-Lung Lin Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines
IL309408A (en) 2021-06-18 2024-02-01 Sanofi Sa Multivalent flu vaccines
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2023056980A1 (zh) * 2021-10-09 2023-04-13 吴可行 自复制rna分子设计及其应用
AU2022372325A1 (en) 2021-10-18 2024-05-02 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
WO2023067124A1 (en) 2021-10-22 2023-04-27 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
WO2023067123A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
WO2023067125A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
AU2022369405A1 (en) 2021-10-22 2024-05-09 BioNTech SE Oligosaccharide compounds and complexes
AR127585A1 (es) 2021-11-05 2024-02-07 Sanofi Sa Vacuna de arn de virus sincicial respiratorio
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
WO2023232747A1 (en) 2022-05-30 2023-12-07 BioNTech SE Complexes for delivery of nucleic acids
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024068674A1 (en) 2022-09-26 2024-04-04 BioNTech SE Nucleic acid complexes and uses thereof
WO2024086549A1 (en) * 2022-10-17 2024-04-25 The University Of North Carolina At Chapel Hill Chimeric alphaviruses for directed evolution
WO2024084462A1 (en) 2022-10-21 2024-04-25 BioNTech SE Nucleic acid complexes and uses thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2353282C (en) * 1998-03-20 2013-02-27 State Queensland Primary Ind Control of gene expression
IL145221A0 (en) 1999-03-09 2002-12-01 Large Scale Biology Corp Unive Multiple component rna vector system for expression of foreign sequences
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
EP2305299B1 (en) * 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimeric alphavirus replicon particles
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
WO2003085114A1 (en) 2002-04-01 2003-10-16 Walter Reed Army Institute Of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
PL2167523T3 (pl) 2007-06-19 2014-12-31 Univ Louisiana State Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA
AU2008266807B2 (en) * 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
EA022990B1 (ru) 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
BR112013000392B8 (pt) * 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
LT4066855T (lt) 2010-08-31 2023-03-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
PT4008357T (pt) 2010-08-31 2023-01-11 Glaxosmithkline Biologicals Sa Lipossomas pequenos para entrega de arn que codifica um imunogénio
ES2716243T3 (es) * 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
EP3424495A1 (en) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
ES2656050T3 (es) * 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
EP2729126B1 (en) 2011-07-06 2020-12-23 GlaxoSmithKline Biologicals SA Liposomes having useful n:p ratio for delivery of rna molecules
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
JP6305925B2 (ja) * 2011-10-11 2018-04-18 ノバルティス アーゲー 組換え自己複製ポリシストロニックｒｎａ分子
BR122019027913B1 (pt) * 2011-11-11 2021-11-30 Variation Biotechnologies, Inc Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
KR20200049856A (ko) * 2017-09-13 2020-05-08 비온테크 알엔에이 파마슈티컬스 게엠베하 세포에서 rna 발현을 향상시키는 방법

Also Published As

Publication number Publication date
EP3433368B1 (en) 2021-10-06
MD3433368T2 (ro) 2021-12-31
KR20180127360A (ko) 2018-11-28
MA44479A (fr) 2021-04-21
CN109328233A (zh) 2019-02-12
JP2019509048A (ja) 2019-04-04
ZA201805520B (en) 2019-11-27
EP3964584A1 (en) 2022-03-09
JP7421256B2 (ja) 2024-01-24
CA3017285A1 (en) 2017-09-28
JP2022020634A (ja) 2022-02-01
BR112018068391A2 (pt) 2019-01-15
JP7105193B2 (ja) 2022-07-22
ES2896927T3 (es) 2022-02-28
WO2017162265A1 (en) 2017-09-28
AU2017236240A1 (en) 2018-09-20
RU2018131783A3 (el) 2020-07-14
IL261327A (en) 2018-10-31
DK3433368T3 (da) 2021-11-15
HUE058889T2 (hu) 2022-09-28
MX2018011384A (es) 2019-02-13
PT3433368T (pt) 2021-11-15
SI3433368T1 (sl) 2022-01-31
SG11201807378SA (en) 2018-10-30
RS62543B1 (sr) 2021-12-31
KR102441725B1 (ko) 2022-09-08
US20200299724A1 (en) 2020-09-24
MA44479B1 (fr) 2021-11-30
EP3433368A1 (en) 2019-01-30
WO2017162461A1 (en) 2017-09-28
RU2018131783A (ru) 2020-04-22
HRP20211715T1 (hr) 2022-02-18
LT3433368T (lt) 2021-11-25
ZA201905396B (en) 2021-03-31
RU2752580C2 (ru) 2021-07-29
CN115386596A (zh) 2022-11-25
IL261327B1 (en) 2024-04-01
AU2017236240B2 (en) 2022-11-17
PL3433368T3 (pl) 2021-12-27
CN109328233B (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
CY1124689T1 (el) Trans-αντιγραφοymeno rna
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
CY1124518T1 (el) Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες
AU2018298422A1 (en) Novel nucleic acid molecules
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
MX2018001040A (es) Moleculas de acido nucleico artificiales.
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
BR112017003108A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
SG10201906673WA (en) Artificial nucleic acid molecules
SG10201903381TA (en) Artificial nucleic acid molecules
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
MX357803B (es) Moléculas de ácido nucleico artificiales.
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA201390689A1 (ru) Консенсусные антигены простаты, молекула нуклеиновой кислоты, кодирующая их, и вакцина, и использование, включающее их
BR112016015187A2 (pt) proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma
EA201992282A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
EA202092990A2 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
PH12020500526A1 (en) Paramyxoviridae expression system
BR112023023260A2 (pt) Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica